Nektar Therapeutics 0UNL.L Stock
Nektar Therapeutics Price Chart
Nektar Therapeutics 0UNL.L Financial and Trading Overview
| Nektar Therapeutics stock price | 1.61 USD |
| Previous Close | 0.57 USD |
| Open | 0 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0 - 0 USD |
| 52 Week Range | 0 - 5.11 USD |
| Volume | 84 USD |
| Avg. Volume | 8.98K USD |
| Market Cap | 994.6K USD |
| Beta (5Y Monthly) | 1.1 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.664 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0UNL.L Valuation Measures
| Enterprise Value | -220554960 USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.011197091 |
| Price/Book (mrq) | 0.4556952 |
| Enterprise Value/Revenue | -2.483 |
| Enterprise Value/EBITDA | 1.465 |
Trading Information
Nektar Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.1 |
| 52-Week Change | -83.25% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.11 USD |
| 52 Week Low | 0 USD |
| 50-Day Moving Average | 0.74 USD |
| 200-Day Moving Average | 2.5 USD |
0UNL.L Share Statistics
| Avg. Volume (3 month) | 8.98K USD |
| Avg. Daily Volume (10-Days) | 23.99K USD |
| Shares Outstanding | 173.08M |
| Float | 175.07M |
| Short Ratio | N/A |
| % Held by Insiders | 1.34% |
| % Held by Institutions | 97.72% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -182.56% |
| Gross Margin | 73.67% |
| EBITDA Margin | -169.50% |
Management Effectiveness
| Return on Assets (ttm) | -12.78% |
| Return on Equity (ttm) | -97.74% |
Income Statement
| Revenue (ttm) | 88.83M USD |
| Revenue Per Share (ttm) | 0.47 USD |
| Quarterly Revenue Growth (yoy) | -13.00000000000000000000000000000000% |
| Gross Profit (ttm) | 70.42M USD |
| EBITDA | -150564992 USD |
| Net Income Avi to Common (ttm) | -414823008 USD |
| Diluted EPS (ttm) | -2.664 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 456.83M USD |
| Total Cash Per Share (mrq) | 2.41 USD |
| Total Debt (mrq) | 128.16M USD |
| Total Debt/Equity (mrq) | 53.21 USD |
| Current Ratio (mrq) | 8.201 |
| Book Value Per Share (mrq) | 1.273 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -267498000 USD |
| Levered Free Cash Flow (ttm) | -75034248 USD |
Profile of Nektar Therapeutics
| Country | United Kingdom |
| State | CA |
| City | San Francisco |
| Address | 455 Mission Bay Boulevard South |
| ZIP | 94158 |
| Phone | 415 482 5300 |
| Website | https://www.nektar.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 216 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Q&A For Nektar Therapeutics Stock
What is a current 0UNL.L stock price?
Nektar Therapeutics 0UNL.L stock price today per share is 1.61 USD.
How to purchase Nektar Therapeutics stock?
You can buy 0UNL.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Nektar Therapeutics?
The stock symbol or ticker of Nektar Therapeutics is 0UNL.L.
How many shares does Nektar Therapeutics have in circulation?
The max supply of Nektar Therapeutics shares is 1.71M.
What is Nektar Therapeutics Price to Earnings Ratio (PE Ratio)?
Nektar Therapeutics PE Ratio is now.
What was Nektar Therapeutics earnings per share over the trailing 12 months (TTM)?
Nektar Therapeutics EPS is -2.664 USD over the trailing 12 months.